Due to the current critical shortage of Dexrazoxane for Injection, 250 mg/vial and 500 mg/vial in the United States (U.S.) market, Clinigen Healthcare Ltd is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of Dexrazoxane for Injection 500 mg/vial. Clinigen Healthcare Ltd has initiated temporary importation into the U.S. of Cardioxane 500 mg Powder for Solution for Infusion (dexrazoxane hydrochloride) to help alleviate the shortage. The Cardioxane 500 mg Powder for Solution for Infusion was manufactured by Cenexi – Laboratoires Thissen S.A. in Belgium and is licensed for sale in the United Kingdom. Orders can be placed from 17 July 2017 with Clinigen Healthcare Ltd’s distributor for Cardioxane in the US, Cumberland Pharmaceuticals Inc., at 615-255-0068. Reference should be made to the Dear Healthcare Professional Letter for important information about the use of this product.